Intrastriatal 6-hydroxydopamine injections in rats induce partial lesions of the nigrostriatal dopamine (DA) system which are accompanied by a delayed and protracted degeneration of DA neurons within the substantia nigra. By careful selection of the dose and placement of the toxin it is possible to obtain reproducible and regionally defined partial lesions which are well correlated with stable functional deficits, not only in drug-induced behaviors but also in spontaneous motoric and sensorimotoric function, which are analogous to the symptoms seen in patients during early stages of Parkinson's disease. The intrastriatal partial lesion model has proved to be particularly useful for studies on the mechanisms of action of neurotrophic factors since it offers opportunities to investigate both protection of degenerating DA neurons during the acute phases after the lesion and stimulation of regeneration and functional recovery during the chronic phase of the postlesion period when a subset of the spared nigral DA neurons persist in an atrophic and dysfunctional state. In the in vivo experiments performed in this model glial cell line-derived neurotrophic factor (GDNF) has been shown to exert neurotrophic effects both at the level of the cell bodies in the substantia nigra and at the level of the axon terminals in the striatum. Intrastriatal administration of GDNF appears to be a particularly effective site for induction of axonal sprouting and regeneration accompanied by recovery of spontaneous sensorimotor behaviors in the chronically lesioned nigrostriatal dopamine system.
INTRODUCTION
Parkinson's disease (PD) is characterized by progressive degeneration of the nigrostriatal dopamine (DA) system that is protracted over years or decades. Symptoms typically do not appear until at least 50% of the DA neurons in the substantia nigra (SN) is lost, at a time when the DA content in the caudatus and putamen may be reduced by about 70-80% (Fearnley & Lees, 1991; McGeer et al., 1988; Riederer & Wuketich, 1976) . The progressive nature of these degenerative changes provides opportunities for therapeutic interventions which may halt the degenerative process and thus prevent an early diagnosed disease from getting worse. In addition, the fact that a significant proportion of the nigral DA neurons persists also in more severe states of the disease, albeit in an atrophic or compromised state, raises the possibility of applying agents that may promote regeneration and functional recovery of the spared neurons in the partially degenerated nigrostriatal DA system.
The standard rodent DA lesion model, which is based on unilateral injections of 6-hydroxydopamine (6-OHDA) into the substantia nigra or the medial forebrain bundle (MFB), has been used extensively in behavioral studies and has been highly useful in both pharmacological experiments and transplantation studies. However, due to the rapid and near-complete
